健脾抑瘤汤辅助治疗对晚期原发性肝癌患者近期疗效、免疫功能及预后生存的影响  

Effects of Jianpi Yiliu Decoction Adjuvant Therapy on Short-term Efficacy,Immune Function and Prognostic Survival of Patients with Advanced Primary Liver Cancer

作　　者：罗洁[1] 刘芳 吴万梅[1] LUO Jie;LIU Fang;WU Wan-mei(Department of Traditional Chinese Medicine for Tumor,Cancer Hospital of Sichuan Province,Chengdu 610041,China)

机构地区：[1]四川省肿瘤医院肿瘤中医科,成都610041

出　　处：《解放军医药杂志》2021年第4期26-29,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：四川省重点研发项目(20ZDYF1199)。

摘　　要：目的分析健脾抑瘤汤辅助治疗对晚期原发性肝癌患者近期疗效、免疫功能及预后生存的影响。方法回顾性分析2017年3月—2018年3月我院收治的103例晚期原发性肝癌患者的临床资料,根据治疗药物不同分为对照组54例与观察组49例。对照组采用常规药物进行治疗;观察组在对照组基础上加用健脾抑瘤汤。比较2组近期疗效、中医证候疗效、治疗前后的免疫功能状况、不良反应及预后生存情况。结果观察组瘤体近期治疗总有效率及中医证候疗效高于对照组(P<0.05);与对照组比较,观察组CD3+、CD4+水平升高,CD8+、CD4+/CD8+降低(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。2组中位生存期、6个月生存率及12、18、24个月累积生存率比较差异无统计学意义(P>0.05)。结论健脾抑瘤汤作为辅助治疗晚期原发性肝癌,不仅可提高患者近期的治疗效果,还可有效改善其免疫功能。Objective To analyze effects of Jianpi Yiliu Decoction adjuvant therapy on short-term efficacy,immune function and prognostic survival of patients with advanced primary liver cancer.Methods Clinical data of 103 patients with advanced primary liver cancer who had admitted during March 2017 and March 2018 was retrospectively analyzed.The patients were divided into control group(n=54)and observation group(n=49)according to different drug treatments.Control group was treated with conventional treatment,while observation group was supplemented with Jianpi yiliu Decoction on the basis of the treatment of control group.The short-term efficacy,efficacy of traditional Chinese medicine syndrome,conditions of immune function before and after treatment,occurrence of adverse reactions and prognostic survival were compared between two groups.Results The total effective rate of recent treatment and efficacy of traditional Chinese medicine syndrome in observation group were higher than that in control group(P<0.05).In observation group,levels of CD3+and CD4+were significantly higher,while levels of CD8+and CD4+/CD8+were significantly lower than those in control group(P<0.05).There was no significant difference in incidence rate of adverse reactions between two groups(P>0.05).There were no significant differences in median survival time,survival rate in the 6 th month,cumulative survival rates in the 12 th month,the 18 th month and the 24 th month between two groups(P>0.05).Conclusion Jianpi Yiliu Decoction adjuvant therapy may not only improve short-term treatment effect,but also effectively improve immune function in patients with advanced primary liver cancer.

关 键 词：肝肿瘤 健脾抑瘤汤 证候 累积存活率 T淋巴细胞亚群 预后 

分 类 号：R735.7[医药卫生—肿瘤]